These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


103 related items for PubMed ID: 16320732

  • 1. Measuring quality of life in multiple sclerosis: not as simple as it sounds.
    Nicholl L, Hobart JC, Cramp AF, Lowe-Strong AS.
    Mult Scler; 2005 Dec; 11(6):708-12. PubMed ID: 16320732
    [Abstract] [Full Text] [Related]

  • 2. The validity and test-retest reliability of the Leeds Multiple Sclerosis Quality of Life scale in Turkish patients.
    Akbiyik DI, Sumbuloglu V, Guney Z, Armutlu K, Korkmaz N, Keser I, Yuksel MM, Karabudak R.
    Int J Rehabil Res; 2009 Jun; 32(2):162-6. PubMed ID: 19369887
    [Abstract] [Full Text] [Related]

  • 3. Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples.
    Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Thompson AJ.
    J Neurol Neurosurg Psychiatry; 2002 Dec; 73(6):701-4. PubMed ID: 12438473
    [Abstract] [Full Text] [Related]

  • 4. Structural and construct validity of the Leeds Multiple Sclerosis Quality of Life scale.
    Ensari I, Motl RW, McAuley E.
    Qual Life Res; 2016 Jun; 25(6):1605-11. PubMed ID: 26660145
    [Abstract] [Full Text] [Related]

  • 5. Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment.
    Lily O, McFadden E, Hensor E, Johnson M, Ford H.
    Mult Scler; 2006 Dec; 12(6):808-13. PubMed ID: 17263011
    [Abstract] [Full Text] [Related]

  • 6. Predictors of quality of life among patients with multiple sclerosis: an Italian cross-sectional study.
    Patti F, Russo P, Pappalardo A, Macchia F, Civalleri L, Paolillo A, FAMS study group.
    J Neurol Sci; 2007 Jan 31; 252(2):121-9. PubMed ID: 17188301
    [Abstract] [Full Text] [Related]

  • 7. Kurtzke scales revisited: the application of psychometric methods to clinical intuition.
    Hobart J, Freeman J, Thompson A.
    Brain; 2000 May 31; 123 ( Pt 5)():1027-40. PubMed ID: 10775547
    [Abstract] [Full Text] [Related]

  • 8. The development of patient-reported outcome indices for multiple sclerosis (PRIMUS).
    Doward LC, McKenna SP, Meads DM, Twiss J, Eckert BJ.
    Mult Scler; 2009 Sep 31; 15(9):1092-102. PubMed ID: 19556315
    [Abstract] [Full Text] [Related]

  • 9. Tests of data quality, scaling assumptions, reliability, and construct validity of the SF-36 health survey in people who abuse heroin.
    Chiu EC, Hsueh IP, Hsieh CH, Hsieh CL.
    J Formos Med Assoc; 2014 Apr 31; 113(4):234-41. PubMed ID: 24685299
    [Abstract] [Full Text] [Related]

  • 10. Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales.
    Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Thompson AJ.
    Mult Scler; 2003 Aug 31; 9(4):411-9. PubMed ID: 12926848
    [Abstract] [Full Text] [Related]

  • 11. Psychometric properties of the SDM-Q-9 questionnaire for shared decision-making in multiple sclerosis: item response theory modelling and confirmatory factor analysis.
    Ballesteros J, Moral E, Brieva L, Ruiz-Beato E, Prefasi D, Maurino J.
    Health Qual Life Outcomes; 2017 Apr 22; 15(1):79. PubMed ID: 28431587
    [Abstract] [Full Text] [Related]

  • 12. Developing a disease-specific quality of life measure for people with multiple sclerosis.
    Ford HL, Gerry E, Tennant A, Whalley D, Haigh R, Johnson MH.
    Clin Rehabil; 2001 Jun 22; 15(3):247-58. PubMed ID: 11386394
    [Abstract] [Full Text] [Related]

  • 13. Psychometric properties of quality of life and health-related quality of life assessments in people with multiple sclerosis.
    Learmonth YC, Hubbard EA, McAuley E, Motl RW.
    Qual Life Res; 2014 Sep 22; 23(7):2015-23. PubMed ID: 24526294
    [Abstract] [Full Text] [Related]

  • 14. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
    Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B.
    Mult Scler; 2010 Aug 22; 16(8):964-9. PubMed ID: 20534644
    [Abstract] [Full Text] [Related]

  • 15. Validation of the Disease-specific Questionnaire MSQoL-54 in Bosnia and Herzegovina Multiple Sclerosis Patients Sample.
    Catic T, Culig J, Suljic E, Masic A, Gojak R.
    Med Arch; 2017 Apr 22; 71(2):103-106. PubMed ID: 28790539
    [Abstract] [Full Text] [Related]

  • 16. [MusiQol: international questionnaire investigating quality of life in multiple sclerosis: validation results for the German subpopulation in an international comparison].
    Flachenecker P, Vogel U, Simeoni MC, Auquier P, Rieckmann P.
    Nervenarzt; 2011 Oct 22; 82(10):1281-9. PubMed ID: 21472450
    [Abstract] [Full Text] [Related]

  • 17. Validation of the World Health Organization Disability Assessment Schedule II (WHODAS-II) in patients with multiple sclerosis.
    Magistrale G, Pisani V, Argento O, Incerti CC, Bozzali M, Cadavid D, Caltagirone C, Medori R, DeLuca J, Nocentini U.
    Mult Scler; 2015 Apr 22; 21(4):448-56. PubMed ID: 25092769
    [Abstract] [Full Text] [Related]

  • 18. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.
    Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A.
    Brain; 2001 May 22; 124(Pt 5):962-73. PubMed ID: 11335698
    [Abstract] [Full Text] [Related]

  • 19. The psychosocial and cognitive impact of longstanding 'benign' multiple sclerosis.
    Sayao AL, Bueno AM, Devonshire V, Tremlett H, UBC MS Clinic Neurologists.
    Mult Scler; 2011 Nov 22; 17(11):1375-83. PubMed ID: 21677023
    [Abstract] [Full Text] [Related]

  • 20. Benefit evaluation in multiple sclerosis relapse treatment from the patients' perspective - Development and validation of a new questionnaire.
    Beckmann H, Augustin M, Heesen C, Poettgen J, Blome C.
    Mult Scler Relat Disord; 2019 Feb 22; 28():256-261. PubMed ID: 30639826
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 6.